Arcutis Biotherapeutics Inc 's Cash & cash equivalent grew by 8.76 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Arcutis Biotherapeutics Inc 's Quick Ratio to 1.51, Quick Ratio remained below Arcutis Biotherapeutics Inc average.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Arcutis Biotherapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1653, from total ranking in the second quarter 2026 at 1682.

Explain Quick Ratio?
How much Cash & cash equivalents ARQT�s has?
What are ARQT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ARQT/financial-strength

https://api.csimarket.com/api/v1/companies/ARQT/fundamentals

https://api.csimarket.com/api/v1/companies/ARQT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ARQT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	72.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	80.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.51	Subscribe	Subscribe	Subscribe	Subscribe
ARQT's Total Ranking	# 1653	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	7.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	8.76 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 320
Healthcare Sector	# 569
Overall Market	# 1653

Quick Ratio Statistics
High	Average	Low
30.67	9.06	1.14
(Jun 30 2021)		(Sep 30 2024)

Financial Statements
Arcutis Biotherapeutics Inc 's Current Liabilities	$ 172 Millions	Visit ARQT's Balance sheet
Arcutis Biotherapeutics Inc 's Cash & cash equivalent	$ 259 Millions	Visit ARQT's Balance sheet
Source of ARQT's Sales		Visit ARQT's Sales by Geography

Cumulative Arcutis Biotherapeutics Inc 's Quick Ratio

ARQT's Quick Ratio for the trailling 12 Months

ARQT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	66.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	35.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.38	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4116	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	13.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	15.41 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ARQT Financial Strength Comparisons >> Go to Compare ARQT Quick Ratio to its Competitors

On the trailing twelve months basis ARQT Cash & cash equivalent soared by 80.25 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Arcutis Biotherapeutics Inc 's Quick Ratio to 1.38, Quick Ratio remained below ARQT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Arcutis Biotherapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3944 to 4116.

Explain Quick Ratio?
How much Cash & cash equivalents ARQT�s has?
What are ARQT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 912
Within the Market	# 4116

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.29	2.71	0.06
(Mar 31 2021)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions
Maia Biotechnology Inc	3.30	$ 21.339 Millions	$ 6.474 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions
Harmony Biosciences Holdings inc	3.02	$ 771.138 Millions	$ 254.981 Millions
Phio Pharmaceuticals Corp	2.96	$ 10.609 Millions	$ 3.583 Millions
Zevra Therapeutics Inc	2.95	$ 122.148 Millions	$ 41.369 Millions
Nextcure Inc	2.95	$ 8.728 Millions	$ 2.960 Millions
Pyxis Oncology Inc	2.79	$ 55.572 Millions	$ 19.942 Millions
Zenas Biopharma Inc	2.78	$ 177.778 Millions	$ 64.043 Millions
Ptc Therapeutics inc	2.74	$ 2,127.918 Millions	$ 776.076 Millions
Annexon Inc	2.72	$ 102.389 Millions	$ 37.660 Millions
Turn Therapeutics Inc	2.71	$ 9.433 Millions	$ 3.479 Millions
Beone Medicines Ltd	2.67	$ 5,955.905 Millions	$ 2,233.923 Millions
Biohaven Ltd	2.57	$ 161.125 Millions	$ 62.767 Millions
Ironwood Pharmaceuticals inc	2.49	$ 86.376 Millions	$ 34.733 Millions
Tg Therapeutics Inc	2.43	$ 632.004 Millions	$ 260.526 Millions
Adc Therapeutics Sa	2.42	$ 189.204 Millions	$ 78.125 Millions
Dermata Therapeutics Inc	2.40	$ 4.822 Millions	$ 2.012 Millions
Opko Health Inc	2.37	$ 384.036 Millions	$ 162.356 Millions
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions

Date modified: 2026-11-07T13:24:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.